Key Highlights
- The GLOW2 Phase 3 trial of Zenkuda successfully achieved its primary endpoint in diabetic retinopathy patients
- A remarkable 62.5% of participants receiving Zenkuda achieved meaningful improvement compared to only 3.3% in the control group
- The treatment demonstrated an 85% reduction in sight-threatening complications versus sham through 48 weeks
- The trial recorded zero instances of intraocular inflammation
- The company is fast-tracking its Biologics License Application filing for Zenkuda
Shares of Kodiak Sciences (KOD) advanced to $22.75 after the announcement, building on a remarkable 656% surge over the preceding 12 months, despite trading down 18.6% since the start of this year.
Kodiak Sciences announced on March 26 that Zenkuda (tarcocimab tedromer) successfully achieved its primary goal in the GLOW2 Phase 3 clinical trial for diabetic retinopathy treatment.
The data revealed compelling superiority over the control group across all evaluated metrics.
Patients receiving Zenkuda achieved a two-step or better improvement on the diabetic retinopathy severity score (DRSS) at 48 weeks in 62.5% of cases. The sham treatment group managed this outcome in merely 3.3% of participants.
This outcome achieved statistical significance with high confidence levels, successfully meeting the study’s primary objective.
Reducing Vision-Threatening Events
The experimental treatment reduced the incidence of prespecified sight-threatening events by 85% compared to sham intervention through the 48-week period. These events encompassed new or worsening proliferative diabetic retinopathy or center-involving diabetic macular edema.
Merely 2.4% of those treated with Zenkuda experienced these complications, contrasted with 15.8% in the control cohort.
Regarding secondary measures, 13.7% of Zenkuda recipients demonstrated a three-step or superior improvement in DRSS, while the sham group registered 0%.
These findings align with the preceding GLOW1 trial, which showed Zenkuda decreased sight-threatening complication risk by 89%.
GLOW2 functioned as a confirmatory investigation to GLOW1, broadening enrollment criteria to incorporate patients with proliferative diabetic retinopathy and mild diabetic macular edema.
Participants underwent Zenkuda injections at study initiation, Week 4, Week 8, Week 20, and Week 44. Every patient transitioned to a 6-month dosing schedule by trial conclusion.
Tolerability and Safety
The medication demonstrated a favorable safety profile throughout the study. Researchers observed zero cases of intraocular inflammation, and no instances of retinal vasculitis or occlusive retinal vasculitis emerged.
Cataract adverse events occurred at a 2.3% rate with Zenkuda versus 1.6% with sham treatment — consistent with anticipated baseline frequencies in diabetic retinopathy populations.
GLOW2 enrolled patients taking GLP-1 receptor agonist therapies, representing a realistic diabetic patient demographic. Approximately 46.1% of Zenkuda recipients and 42.4% of sham participants were utilizing GLP-1 medications.
Within the Zenkuda cohort using GLP-1 therapies, 60.0% reached the primary endpoint, compared to 64.3% among non-users — a minimal differential indicating GLP-1 usage had negligible influence on treatment response.
The biotechnology company stated it will expedite its Biologics License Application submission schedule for Zenkuda following the encouraging GLOW2 results.
H.C. Wainwright maintains a Buy recommendation on KOD shares with a $38 price objective. UBS similarly holds a Buy rating with a $50 target price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
